Cargando…
Effect of sodium–glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial
BACKGROUND: Amelioration of proteinuria is one of main treatment targets in patients with glomerulonephritis, yet the remission rates are suboptimal. AIM OF THE STUDY: To examine the effect of the sodium–glucose transporter 2 inhibitor (empagliflozin) on proteinuria and kidney function progression,...
Autores principales: | Hammad, Hany, Shaaban, Asmaa, Philips, Mariana Victor, Fayed, Ahmed, Abdelaziz, Tarek Samy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406661/ https://www.ncbi.nlm.nih.gov/pubmed/36872420 http://dx.doi.org/10.1007/s11255-023-03539-8 |
Ejemplares similares
-
Infection-related Glomerulonephritis and C3 Glomerulonephritis - Similar Yet Dissimilar: A Case Report and Brief Review of Current Literature
por: Chamarthi, Gajapathiraju, et al.
Publicado: (2020) -
Immune Check Point Inhibitor–Associated Glomerulonephritis
por: Ashour, Tarek, et al.
Publicado: (2018) -
A Case of Colon Cancer and Pauci-Immune Crescentic Glomerulonephritis
por: Wilhelm, David, et al.
Publicado: (2022) -
IgA-dominant postinfectious glomerulonephritis: a case report
por: Moreno-Alvarado, Rodolfo, et al.
Publicado: (2023) -
Endocarditis-Associated C3-Dominant Glomerulonephritis in a Patient With a Solitary Kidney
por: Chowdhury, Lynda, et al.
Publicado: (2022)